Brandenberger
Joel Brandenberger, Au CH
Patent application number | Description | Published |
---|---|---|
20150251315 | Process for Finding A Path in an Automated Handling System, and Handling System with Corresponding Control Module for Finding A Path - An Automated handling system has a working area, at least one object in the working area, at least a first numerically controlled arm and at least a second numerically controlled arm. The arms are movable above the working area and have a collision avoidance mechanism. The current actual topography of the working area is determinable, a movement planning algorithm determines a path from a first position to a second position, wherein in the first application of the movement planning algorithm a reference path, a quasi-static collision examination for the path, which has been provided by the movement planning algorithm, is applicable, a dynamic collision examination for the path, which has been suggested by the movement planning algorithm, is applicable, and wherein the collision examination determine whether, when moving the first arm a collision would be provoked. | 09-10-2015 |
Philip J. Brandenberger, Montclair, NJ US
Patent application number | Description | Published |
---|---|---|
20140040658 | Disaster Recovery Framework - A System and method of orchestrating failover operations of servers providing services to an internal computer network includes a DR server configured to execute a control script that performs a failover operation. Information needed to perform the failover operation is stored on the DR server thereby eliminating the need to store agents on each of the application's primary and backup servers. The DR server may provide a centralized location for the maintenance an update of the failover procedures for the internal network's redundant services. A failover operation may be initiated by an authorized user in communication with the internal computer network. | 02-06-2014 |
Ralph Brandenberger, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20090191626 | Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells - Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media. | 07-30-2009 |
20090191633 | Synthetic Surfaces for Culturing Stem Cell Derived Cardiomyocytes - Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media. | 07-30-2009 |
20100248366 | Synthetic Surfaces for Differentiating Stem Cells into Cardiomyocytes - Synthetic surfaces capable of supporting culture of eukaryotic cells including stem cells and undifferentiated human embryonic stem cells in a chemically defined medium include a swellable (meth)acrylate layer and a polypeptide conjugated to the swellable (meth)acrylate layer. The swellable (meth)acrylate layer may be formed by polymerizing monomers in a composition that includes a carboxyl group-containing (meth)acrylate monomer, a cross-linking (di- or higher-functional) (meth)acrylate monomer, and a hydrophilic monomer capable of polymerizing with the carboxyl group-containing (meth)acrylate monomer and the cross-linking (meth)acrylate monomer. The swellable (meth)acrylate layer has an equilibrium water content in water of between about 5% and about 70%. The conjugated peptide may include an RGD amino acid sequence. | 09-30-2010 |
20120276626 | SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED CARDIOMYOCYTES - Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media. | 11-01-2012 |
20140134725 | SYNTHETIC SURFACES FOR CULTURING STEM CELL DERIVED CARDIOMYOCYTES - Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media. | 05-15-2014 |
20140134729 | Synthetic Surfaces for Culturing Stem Cell Derived Oligodendrocyte Progenitor Cells - Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media. | 05-15-2014 |
Ralph Brandenberger, Melno Park, CA US
Patent application number | Description | Published |
---|---|---|
20090263835 | Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells - Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy. | 10-22-2009 |